Doxorubicin
Doxorubicin is an anthracycline chemotherapeutic agent used as a cytotoxic therapy across a broad range of malignancies, including breast cancer, diffuse large B-cell lymphoma, osteosarcoma and other sarcomas, leukemias, hepatocellular carcinoma, and other solid tumors.
Doxorubicin is an anthracycline chemotherapeutic agent used as a cytotoxic therapy across a broad range of malignancies, including breast cancer, diffuse large B-cell lymphoma, osteosarcoma and other sarcomas, leukemias, hepatocellular carcinoma, and other solid tumors. It is given intravenously, most often as part of multi-agent regimens — for example alongside cyclophosphamide, rituximab, and prednisone in lymphoma, or with paclitaxel, carboplatin, or gemcitabine in solid tumors — and is also formulated as a liposomal preparation to alter its distribution and toxicity profile. Its antitumor activity derives principally from intercalation into human DNA and poisoning of topoisomerase II, which stabilizes cleavage complexes and produces double-strand breaks, stalling replication and driving TP53-dependent DNA damage responses and apoptosis. Redox cycling of the quinone moiety generates reactive oxygen species, contributing both to tumor cell killing — including through ferroptosis and, through other mechanisms, glutathione depletion — while the Nrf2–SLC7A11–GSH axis can counter oxidative stress — and to off-target injury. Doxorubicin is intrinsically fluorescent, which has made it a convenient model cargo in nanomedicine, prodrug, and drug-delivery imaging studies.
Clinical use is constrained by cumulative dose-dependent cardiotoxicity and by acquired resistance. Resistance mechanisms include efflux by p-glycoprotein, enhanced antioxidant capacity through glutathione and superoxide dismutase, anti-apoptotic signaling via Bcl-2, and cytoskeletal and focal adhesion remodeling. Resistance is also shaped by the tumor microenvironment: cancer-associated fibroblasts, macrophages, and reprogrammed tumor endothelial cells supply angiocrine and NF-κB-dependent cytokine signals, while inflammatory and invasive mediators such as Tnf-α, MMP-2, MMP-9, COX-2, and VEGFR2 signaling accompany adaptive escape. These limitations motivate ongoing work on nanoparticle and hyaluronan-based delivery, prodrug design, and combinations with targeted agents such as sorafenib, with immune checkpoint blockade including anti-Programmed cell death 1 (PD-1) antibodies such as pembrolizumab and nivolumab, with antibody–drug conjugates, and with radiotherapy or physical modalities intended to potentiate doxorubicin-induced cell death.
Where the papers sit
104 papers from the last 6 months study doxorubicin directly · updated from PubMed 14 Nov 2026
Study type 1 clinical trial · 1 observational · 8 human data · 91 preclinical · 3 unclassified
Themes 7 themes · 1 paradigm shift · 1 new direction
-
Targeted Drug Delivery
Responsive carriers are moving doxorubicin toward controlled, tumor-localized delivery rather than free-drug exposure. Acidic, redox-, enzyme-, lactate-, and temperature-sensitive systems aim to trigger release after tumor entry. Liposomes, nanogels, hydrogels, exosomes, porous silicon, and polymer conjugates recur across the work. Better penetration, biocompatibility, and reduced systemic toxicity remain the central goals.
28 papers · 26.9%
-
Breast Cancer Combination Therapy
Breast cancer studies increasingly pair doxorubicin with photothermal, immune, peptide, botanical, or magnetic treatments. Exosomes, lipid nanocarriers, DNA platforms, hydrogels, and fullerene complexes are used to improve uptake and synchronize combination activity. Triple-negative and multidrug-resistant models recur, alongside MCF-7 and MDA-MB-231 systems and 2D, 3D, and animal testing. Membrane permeability, autophagy, mitotic slippage, and drug exposure are the main determinants of response.
16 papers · 15.4%
-
Oxidative Cell Death
Reactive oxygen species and glutathione control are being used to intensify ferroptosis, pyroptosis, and other forms of chemotherapy-induced cell death. Iron nanozymes, metal-organic frameworks, nitric oxide, and mitochondria-targeted systems seek stronger tumor killing through redox amplification. Cardiotoxicity remains the counterproblem, with luteolin, HDAC inhibition, and pyroptosis modulation proposed as protective strategies. The balance between oxidative efficacy and cardiac injury is still unresolved.
15 papers · 14.4%
-
Tumor Microenvironment Therapy
Tumor microenvironment-responsive systems are combining doxorubicin with immunotherapy, photothermal therapy, or chemodynamic treatment. Acidic conditions, glutathione, collagen, and extracellular matrix barriers recur as targets for selective activation and deeper penetration. Hydrogels, bacteria, magnetic particles, and engineered nanoplatforms aim to localize treatment while promoting immunogenic cell death. Breast, ovarian, pancreatic, brain, eye, and bone tumors are represented, with delivery and immune activation tightly linked.
15 papers · 14.4%
-
Doxorubicin Resistance
Resistance research is shifting from tumor-cell survival alone toward cytoskeletal, autophagic, stromal, and immune mechanisms. Paxillin remodeling, TGF-β2-HMGB1 signaling, endothelial angiocrine signals, tunnelling nanotubes, and epithelial-mesenchymal transition recur as resistance drivers. Metformin, targeted conjugates, dual-cargo micelles, and peptide-directed nanoparticles are being tested to restore sensitivity. Dose delays and reductions remain clinically important because resistance biology and treatment intensity both affect outcomes.
13 papers · 12.5%
-
Glioblastoma Drug Delivery
Glioblastoma delivery is moving toward nanoparticles that exploit transferrin, ferritin, albumin, or postoperative blood-brain barrier disruption. Deep tumor penetration and access to the resection margin are recurring goals, with nanomotors and self-assembled carriers addressing physical barriers. The broader cluster also links doxorubicin injury to oxidative stress, mitochondrial dysfunction, senescence, and pyroptosis in heart, kidney, and stem cells. Targeted brain delivery and protection of normal tissues remain complementary priorities.
9 papers · 8.7%
-
Others — Broad Cancer Pharmacology
Cancer therapy, delivery, and toxicity appear together without a single dominant disease or mechanism. Hepatocellular carcinoma studies emphasize immune activation, cellular accumulation, and Caspase-3 signaling. Other papers address cardiotoxicity, lymphoma, glioblastoma, nasopharyngeal carcinoma, and PARP-1/EGFR inhibition. The cluster therefore supports no clear shared therapeutic direction.
8 papers · 7.7%
Doxorubicin-containing platforms can make regulated non-apoptotic death pathways central to therapy
The all-in-one iron-based MOF nanomissile for multimodal tumor therapy and the DOX-loaded nanoflower platform for glioblastoma were each designed around a death mechanism beyond conventional doxorubicin cytotoxicity: ferroptosis through reactive-oxygen-species generation, glutathione depletion, GPX4 downregulation, and lipid-peroxide accumulation in the former, and disulfidptosis through H₂S/DOX-mediated metabolic and mitochondrial disruption in the latter 43007759Nov 43007758Nov. Together, these studies replace the set’s prevailing apoptosis-centered account with a model in which doxorubicin-containing treatment can be used to drive distinct non-apoptotic death programs, while also engaging immunogenic cell death or phototherapy.
Doxorubicin is treated as a self-assembling structural component whose nanocrystal maturation determines formulation performance
The study of PEGylated liposomal doxorubicin examined the drug’s intraliposomal sulfate nanocrystals during remote loading rather than using doxorubicin simply as a therapeutic payload 42815645Sep. It found that rapid drug uptake and high encapsulation efficiency do not establish a finished formulation: sub-mature aggregates undergo later lattice optimization, and insufficient maturation produces burst release. This gives doxorubicin a new materials-engineering role, making post-loading crystal maturation and manufacturing time key determinants of the drug product’s function.
Papers
The 104 papers from the last 6 months that study doxorubicin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Targeted Drug Delivery (28)
- Gold Nanourchins Potentiate Intravesical Chemotherapy by Accelerating Drug Internalization within a Short Instillation Window. ACS nano · 27 Oct 2026 PMID 42937593
- Vitamin B12-Functionalized Nanogels for pH-, and Redox-Responsive Doxorubicin Delivery. Chembiochem : a European journal of chemical biology · 26 Oct 2026 PMID 42929280
- Sequential Dual Nanoparticle Approach for Extracellular Matrix Remodeling and Targeted Chemotherapy through Liposome-Exosome Hybridization in Pancreatic Cancer. ACS applied materials & interfaces · 15 Oct 2026 PMID 42880885
- Folic Acid-Functionalized Liposomes Co-Loaded with Doxorubicin and Indocyanine Green for Combined Chemophotothermal Therapy of Cervical Cancer. ACS applied materials & interfaces · 13 Oct 2026 PMID 42868217
- Anisotropic microgels for spatiotemporal co-delivery of anticancer drugs. Journal of materials chemistry. B · 12 Oct 2026 PMID 42862621
- Surface engineering of liposomes with quaternized hyaluronate for reduced toxicity and enhanced doxorubicin delivery. Journal of materials chemistry. B · 9 Oct 2026 PMID 42853083
- pH-Responsive Covalent Organic Framework-based Nanocarrier for Targeted Delivery of Cancer Therapeutics. ChemMedChem · 9 Oct 2026 PMID 42850959
- Nanocrystal maturation in doxorubicin liposomes determines functional performance: real-time insights from in situ SAXS. Journal of controlled release : official journal of the Controlled Release Society · 30 Sept 2026 PMID 42815645
- An injectable kappa-carrageenan/konjac-glucomannan microgel platform for localized and controlled release of doxorubicin-loaded biomimetic nanoparticles. Carbohydrate polymers · 3 Sept 2026 PMID 42692648
- Zwitterionic PEGylation of Nanodrugs for Reduced Immunogenicity and Improved Drug Delivery Efficacy. ACS applied materials & interfaces · 1 Sept 2026 PMID 42680140
- Dual-targeting poly(2-oxazoline)-coated porous silicon nanoparticles for improving osteosarcoma therapy. Nanoscale · 1 Sept 2026 PMID 42677776
- pH-sensitive polymer-drug conjugate: An approach to evaluate the effect of the linker on doxorubicin release. Journal of pharmaceutical sciences · 21 Aug 2026 PMID 42628647
- Thermosensitive Block Copolymer Hydrogel with Embedded Catanionic Vesicles as a Localized Doxorubicin Delivery Platform for Melanoma. ACS applied bio materials · 27 Jul 2026 PMID 42504495
- Anti-PEG Single-Chain Variable-Fragment Antibody-Assisted In Vivo Process Decoding of PEGylated Nanomedicines. ACS nano · 27 Jul 2026 PMID 42503863
- A clinical data- and AI-supported engineered fusion vesicle system for enhanced tumor-targeted drug delivery and immunochemotherapeutic synergy. Journal of controlled release : official journal of the Controlled Release Society · 22 Jul 2026 PMID 42486279
- Biodegradable dual-responsive amino acid-based zwitterionic nanogels for enhanced cancer therapy. Journal of materials chemistry. B · 20 Jul 2026 PMID 42475274
- Hybrid Response Surface-Machine Learning Optimization of Doxorubicin-Loaded Chitosan Nanoparticles. ACS applied bio materials · 15 Jul 2026 PMID 42454628
- Mechanistic evaluation of liposome-amyloid composite nanocarriers for doxorubicin delivery: Linking release kinetics with pharmacokinetic behavior. Biochimica et biophysica acta. Biomembranes · 11 Jul 2026 PMID 42435790
- pH-responsive microneedle patches based on poly(dextran-co-methacrylic acid) hydrogels for controlled drug release. International journal of biological macromolecules · 9 Jul 2026 PMID 42425357
- Dual-trigger hyaluronic acid nanoprodrug incorporating a 2-nitrobenzenesulfonyl linker for CD44-targeted and glutathione-responsive drug delivery. International journal of pharmaceutics · 4 Jul 2026 PMID 42401301
- Graphene oxide functionalized with polyamidoamine dendrimer as a drug delivery system for human breast cells. Biomaterials advances · 2 Jul 2026 PMID 42391792
- Done EAZY: An Automated Procedure for 89Zr-Radiolabeling and Size-Exclusion Chromatography Purification of Nanoliposomal Anticancer Therapeutics. Molecular pharmaceutics · 29 Jun 2026 PMID 42367047
- Tailored crystallization of CaCO3 vaterite particles using ethylene glycol and carbohydrate-based biopolymers: Structure-function relationship for drug delivery. International journal of biological macromolecules · 22 Jun 2026 PMID 42331154
- Lactate-sensitive nanomachines for enzyme-controlled drug delivery in cancer therapy. Journal of materials chemistry. B · 16 Jun 2026 PMID 42300004
- Programmable nanocarriers with reversible ligand shielding and acid-triggered burst release for sequential tumor penetration and intracellular drug delivery. Colloids and surfaces. B, Biointerfaces · 15 Jun 2026 PMID 42296941
- Functionalization of cyclotriveratrilene with tetrazole and phenothiazine for doxorubicin coordination and delivery. Bioorganic & medicinal chemistry · 10 Jun 2026 PMID 42269374
- Biomimetic Nanoparticles Based on Tumor Cell Membrane Co-loaded with Vitamin E and Doxorubicin for Targeted Synergistic Treatment of Bladder Cancer. ACS applied bio materials · 1 Jun 2026 PMID 42223068
- Effective ropivacaine delivery using lipid nanoparticles enables simultaneous cancer therapy and pain control. International journal of pharmaceutics · 31 May 2026 PMID 42219130
Breast Cancer Combination Therapy (16)
- Evaluation of the antitumor effects of banana extract alone and with doxorubicin in a rat model of breast cancer. Medical oncology (Northwood, London, England) · 9 Nov 2026 PMID 43002330
- Dual-template molecular imprinting enables fully synthetic phosphatidylserine-targeted cancer therapy. Nanoscale · 16 Oct 2026 PMID 42885584
- Autophagy-associated exosomal microRNAs in triple-negative breast cancer: a discovery-phase study. Molecular biology reports · 22 Aug 2026 PMID 42631761
- Synergistic magnetic nano-chemotherapy overcomes chemoresistance in 3D breast cancer models. Mikrochimica acta · 3 Aug 2026 PMID 42545398
- Differential cellular responses of breast cancer and non-tumorigenic mammary epithelial cells to a fullerene-doxorubicin complex. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 29 Jul 2026 PMID 42526255
- Ionic Liquid-Integrated Interpenetrating Polymer Hydrogel for Injectable, Self-Healing, and Stimuli-Responsive Co-Delivery of Protein and Chemotherapeutic Agents in Breast Cancer Therapy. ACS applied bio materials · 27 Jul 2026 PMID 42504456
- Tailoring pH-responsive charge-conversional interfaces in ionizable lipid-based nanoliposomes for synchronized co-delivery and synergistic therapy of triple-negative breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 23 Jul 2026 PMID 42492401
- Rutin-enabled improved systemic exposure of doxorubicin via nanostructured lipid carriers: a proof of concept through novel LC-MS/MS analysis. Drug development and industrial pharmacy · 11 Jul 2026 PMID 42435317
- Pulsed Electromagnetic Field Increases Doxorubicin-induced Mitotic Slippage in MDA-MB-231 Breast Cancer Cells. Anticancer research · 29 Jun 2026 PMID 42373288
- Synergistic anticancer activity of antimicrobial peptide nisin and doxorubicin against breast cancer cells via modulation of membrane permeability. PloS one · 23 Jun 2026 PMID 42335141
- An intelligent responsive nanoplatform based on a DNA nanoflowers/Mn:CuS hybrid for targeted and synergistic cancer therapy. Journal of materials chemistry. B · 16 Jun 2026 PMID 42300245
- Co-Delivery of Chemo and Immune Drugs by Prussian Blue Nanocubes for Combinational Therapy and T1-T2W MR Imaging of MDA-MB-231. ACS applied bio materials · 16 Jun 2026 PMID 42299821
- Exosomes as Biomimetic Nanoplatforms for Synergistic Targeted Chemotherapy and Photothermal Treatment of Breast Cancer. Journal of biochemical and molecular toxicology · 15 Jun 2026 PMID 42290533
- Multifunctional DNA Nanoplatform Based on CuInS/ZnS QDs and Rolling Circle Amplification for Synergistic PTT/CDT/CT of Multidrug Resistant Cancer Cells. ACS applied materials & interfaces · 12 Jun 2026 PMID 42281380
- Dual-functional MXene-integrated GelMA microspheres for synergistic chemo/photothermal therapy: In vitro 2D/3D multi-cancer evaluation and in vivo breast cancer validation. International journal of biological macromolecules · 7 Jun 2026 PMID 42251874
- Bioinspired polydopamine interfacial engineering of plant-derived exosomes enhances doxorubicin bioactivity in 2D and 3D breast cancer models. Biomaterials advances · 27 May 2026 PMID 42202649
Oxidative Cell Death (15)
- Efficacy comparison of 9 chemotherapy regimens in nonmetastatic Ewing's sarcoma treatment: A network meta-analysis. Medicine · 13 Nov 2026 PMID 43024289
- All-in-One Mitochondria-Targeted Iron-Based MOF "Nanomissiles" for Synergistically Potentiated Tumor Ferroptosis, Dual Phototherapy, and Chemotherapy. ACS nano · 10 Nov 2026 PMID 43007759
- HDAC inhibition via suberoylanilide hydroxamic acid ameliorates doxorubicin-induced cardiotoxicity. Nature communications · 4 Sept 2026 PMID 42697879
- Arginine-engineered gold nanoclusters for doxorubicin chemiluminescence sensing. Mikrochimica acta · 29 Aug 2026 PMID 42667424
- Drug delivery systems modified with cell-penetrating peptide tat and folate reverse multidrug resistance in ovarian and colorectal cancer by endocytosis-mediated efficient uptake and energy production reduction. Biomedical materials (Bristol, England) · 28 Aug 2026 PMID 42665012
- Integrated Multi-omics Reveals CDKN1A Suppression and Metabolic Regulation as Key Mechanisms of Huangqi Guizhi Wuwu Decoction Against Doxorubicin-Induced Cardiotoxicity. Cardiovascular toxicology · 21 Aug 2026 PMID 42627580
- A bidirectional pyroptosis regulation strategy to resolve cardiotoxicity-antitumor efficacy dilemma of doxorubicin. Nanoscale · 4 Aug 2026 PMID 42548175
- Metal-dependent cell death in doxorubicin-induced cardiotoxicity and mitigation by luteolin: Network pharmacology and experimental verification. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 30 Jul 2026 PMID 42531631
- Cellular effects of combined Ctn-2 peptide and doxorubicin treatment in breast cancer cells: A preliminary study of membrane interaction, ROS production, and cell cycle distribution. Molecular biology reports · 25 Jul 2026 PMID 42501149
- Dual-responsive self-assembled nanomicelle based on low molecular weight chitosan enhanced the antitumor effect of doxorubicin by disrupting intracellular redox homeostasis. Carbohydrate research · 14 Jul 2026 PMID 42447726
- Anticancer Effects of Nortriptyline Hydrochloride in Osteosarcoma Cells Including Doxorubicin-resistant Cells. Anticancer research · 29 Jun 2026 PMID 42373283
- Surface engineering of graphene as a novel nano-carrier for doxorubicin using sugar-based deep eutectic systems. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 29 Jun 2026 PMID 42372833
- Synergistic drug repurposing strategy identifies doxorubicin and paclitaxel as potential combination therapy for diffuse large B-cell lymphoma. Computers in biology and medicine · 3 Jun 2026 PMID 42235267
- Casein-coated Fe3O4 nanozymes with enhanced peroxidase-like activity for synergistic doxorubicin delivery and catalytic anticancer therapy. Journal of biotechnology · 28 May 2026 PMID 42208681
- Nitric oxide dual-enhanced nanosystem boosts ferroptosis-chemotherapy synergy for tumor therapy. Scientific reports · 26 May 2026 PMID 42192119
Tumor Microenvironment Therapy (15)
- Dual-Responsive Dextran-Based Nanosystem for NIR Dual-Modal Imaging-Guided Photothermal-Chemotherapy of Breast Cancer. Biomacromolecules · 9 Nov 2026 PMID 43002041
- Effects of Alendronate and Alfacalcidol on Preventing Bone Loss in Chemotherapy-treated Soft-tissue Sarcoma. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957265
- Alpha-mangostin combined with doxorubicin-loaded hydrogel for the treatment of ovarian cancer. Journal of materials chemistry. B · 26 Oct 2026 PMID 42929270
- iRGD-Functionalized Graphene-Silver Nanohybrids for Enhanced Blood-Brain Barrier Transport and Tumor Penetration in Glioma Models. ACS applied bio materials · 12 Oct 2026 PMID 42861629
- Tumor microenvironment-responsive injectable hydrogels for localized therapy of pancreatic cancer. Biochemical and biophysical research communications · 4 Oct 2026 PMID 42829994
- Collagen targeting IL-12 combined with Doxorubicin enhances the anti-tumor effect against osteosarcoma. Journal of controlled release : official journal of the Controlled Release Society · 26 Sept 2026 PMID 42800477
- Bacteria-Based Ammunition for Cascade-Amplified Chemoimmunotherapy of Ovarian Cancer. Nano letters · 9 Sept 2026 PMID 42715039
- Dual delivery of immunostimulatory oligonucleotides and doxorubicin by magnetic nanoparticles and metal-organic frameworks for antitumor immunotherapy. Acta biomaterialia · 18 Aug 2026 PMID 42612942
- pH-Responsive hyaluronic acid-based nanoplatform for prolonged intraocular retention and synergistic chemotherapy of retinoblastoma. International journal of biological macromolecules · 16 Aug 2026 PMID 42604682
- Multicomponent Micelles with Boosted Stability of Iminoboronates. Biomacromolecules · 3 Jul 2026 PMID 42397949
- GSH-activatable rare-earth nanoprobe for NIR-II fluorescence imaging-guided surgery and enhanced chemotherapy/chemodynamic therapy of breast cancer. Cancer letters · 11 Jun 2026 PMID 42276408
- A charge-reversible hyaluronic acid prodrug nanoplatform for synergistically enhanced tumor-targeted doxorubicin delivery. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 6 Jun 2026 PMID 42250822
- Focused acoustic vortex-mediated targeted aggregation of engineered bacteria for in situ antibody production to enhance immunotherapy. Acta biomaterialia · 30 May 2026 PMID 42217659
- Development of a Light-Triggered Biotin-Bioorthogonal System for Targeted Anti-Tumor Therapy. Journal of medicinal chemistry · 26 May 2026 PMID 42187134
- A microphysiological spheroid system for modeling glioblastoma structure and therapy response. Biochemical and biophysical research communications · 22 May 2026 PMID 42172901
Doxorubicin Resistance (13)
- Metformin sensitizes HepG2 liver cancer cells to doxorubicin through epithelial to mesenchymal transition and microRNA regulation. Medical oncology (Northwood, London, England) · 10 Nov 2026 PMID 43007581
- Comparative analysis of cytotoxicity, apoptosis, and tumor-progression gene expressions in MCF-7 breast cancer cells treated with Ribociclib, Everolimus, and Doxorubicin: An integrative bioinformatics and experimental study. Molecular biology reports · 10 Nov 2026 PMID 43007495
- Heart-lung-on-a-chip featuring dynamic flow-resistance capture for drug-associated cardiac dysfunction assessment under tumor-immune-conditioned drug exposure. Lab on a chip · 30 Sept 2026 PMID 42813410
- TGF-β2 promotes autophagy-mediated resistance to doxorubicin in metastatic colon cancer cells via HMGB1. Medical oncology (Northwood, London, England) · 25 Sept 2026 PMID 42789212
- Assessing the effect of chemotherapy dose reductions and time delay on event-free survival in Ewing Sarcoma: A retrospective analysis of the Euro Ewing 2012 trial. European journal of cancer (Oxford, England : 1990) · 21 Sept 2026 PMID 42766959
- Dual delivery of metformin and doxorubicin via the gum acacia-gelatin nanohydrogel disrupts tunnelling nanotube-mediated breast cancer progression. Biomaterials science · 17 Aug 2026 PMID 42605874
- Dual-cargo polymeric micelles with tumor-cell/stroma dual-targeting for synergistic eradication of drug-resistant breast cancer. Biomaterials science · 10 Aug 2026 PMID 42572978
- Design, Synthesis, and In Vitro Evaluation of a PSMA-Targeted Doxorubicin Conjugate. ChemMedChem · 31 Jul 2026 PMID 42538127
- A scheme to tackle the dilemma from hepatoma cells under doxorubicin-resistant surroundings: a brightness or a silhouette. Artificial cells, nanomedicine, and biotechnology · 22 Jul 2026 PMID 42482449
- Tumour endothelial cell reprogramming orchestrates angiocrine signalling to drive chemoresistance in breast cancer. Angiogenesis · 22 Jun 2026 PMID 42329467
- Multi-Omics Analysis Identifies Paxillin as a Biomarker of Doxorubicin Resistance via Cytoskeletal Remodeling and Immune Exhaustion. Journal of proteome research · 18 Jun 2026 PMID 42313513
- Colloidal virus-like nanoparticles for targeted delivery of doxorubicin to non-small cell lung cancer using a cell-internalizing peptide. Colloids and surfaces. B, Biointerfaces · 13 Jun 2026 PMID 42287827
- Assessment of Doxorubicin Internalization and Cytotoxicity in Primary Tumor Spheroids After Collagen Digestion. Current protocols · 1 Jun 2026 PMID 42222873
Glioblastoma Drug Delivery (9)
- Self-Crosslinked Albumin Nanoparticles for Targeted Doxorubicin Delivery in Glioblastoma. Biomacromolecules · 9 Nov 2026 PMID 43002039
- Bone marrow mesenchymal stem cells-derived exosomes ameliorate doxorubicin-induced nephrotoxicity via the modulation of pyroptosis-associated signaling. Molecular medicine (Cambridge, Mass.) · 31 Oct 2026 PMID 42963580
- Ferritin-Based Nanomotors for Deep Glioblastoma Penetration and Enhanced Drug Delivery. Macromolecular bioscience · 30 Sept 2026 PMID 42814085
- Shikonin attenuates doxorubicin-induced myocardial senescence and fibrosis in association with improved redox and mitochondrial homeostasis. Molecular biology reports · 28 Sept 2026 PMID 42803853
- Novel pyrimidine nucleoside - chitosan - silybin micelles for improving the oral absorption of doxorubicin via intestinal nucleoside transporter. Carbohydrate polymers · 24 Sept 2026 PMID 42785882
- Transferrin-Conjugated Polymeric Nanoparticles via Polymerization-Induced Self-Assembly for Enhanced BBB Transport and Glioblastoma Therapy. ACS applied bio materials · 17 Aug 2026 PMID 42606070
- Doxorubicin-Induced Cytotoxicity in Adipose-Derived Stem Cells Is Associated With Altered SAPK/JNK Signaling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 31 Jul 2026 PMID 42533549
- Targeting therapeutic nanoparticles to the glioblastoma resection margin by harnessing postoperative blood-brain barrier disruption. Science translational medicine · 29 Jul 2026 PMID 42525789
- Self-Assembly, Phase Behavior, and Structure of Phenylalanine Alkyl Esters: Characterization of Lauryl Phenylalaninate-Lauryl Sulfate Catanionic Liposomes and Doxorubicin Encapsulation and Release. Langmuir : the ACS journal of surfaces and colloids · 20 May 2026 PMID 42159400
Others — Broad Cancer Pharmacology (8)
- Disulfidptosis-Driven Immune-Activated Multimodal Therapy for Glioblastoma with Systemic Safety Control. ACS nano · 10 Nov 2026 PMID 43007758
- Correlating the C-5 Induction Effect on Uracil-Based Nucleoside Lipid Nanoparticles for Enhanced Redox-Mediated Therapeutic Efficacy in Hepatocellular Carcinoma. ACS applied bio materials · 5 Oct 2026 PMID 42834024
- Cholesterol-mediated endoplasmic reticulum targeting to enhance the immune-activating capability of doxorubicin for hepatocellular carcinoma. International journal of pharmaceutics · 19 Sept 2026 PMID 42763080
- Doxorubicin-loaded chitosan-silver nanocarrier elicits chemoresistance in liver cancer cells. Medical oncology (Northwood, London, England) · 14 Aug 2026 PMID 42599562
- Clinical Outcomes of Pola-R-CHP Therapy in Patients Aged >80 Years With Diffuse Large B-Cell Lymphoma. Anticancer research · 29 Jun 2026 PMID 42373284
- Downregulation of SLC44A4 in nasopharyngeal carcinoma is associated with malignant progression, B-cell/TLS-related immune features, and sensitivity to DNA-damaging agents. PloS one · 26 Jun 2026 PMID 42361082
- Laser-programmable glycosaminoglycan-based nanocarriers co-deliver hypocrellin B and doxorubicin for spatiotemporal chemo-photothermal therapy of hepatocellular carcinoma. Colloids and surfaces. B, Biointerfaces · 20 Jun 2026 PMID 42322922
- Molecular Boomerangs Against Cancer: Design, Synthesis, Biological Evaluation, and In Silico Study of Novel Dual PARP-1/EGFR Inhibitors. Drug development research · 28 May 2026 PMID 42207930
By study type
Clinical trials (1)
- Assessing the effect of chemotherapy dose reductions and time delay on event-free survival in Ewing Sarcoma: A retrospective analysis of the Euro Ewing 2012 trial. European journal of cancer (Oxford, England : 1990) · 21 Sept 2026 PMID 42766959
Observational studies and case reports (1)
- Clinical Outcomes of Pola-R-CHP Therapy in Patients Aged >80 Years With Diffuse Large B-Cell Lymphoma. Anticancer research · 29 Jun 2026 PMID 42373284
Human data, design not indexed (8)
- Efficacy comparison of 9 chemotherapy regimens in nonmetastatic Ewing's sarcoma treatment: A network meta-analysis. Medicine · 13 Nov 2026 PMID 43024289
- Comparative analysis of cytotoxicity, apoptosis, and tumor-progression gene expressions in MCF-7 breast cancer cells treated with Ribociclib, Everolimus, and Doxorubicin: An integrative bioinformatics and experimental study. Molecular biology reports · 10 Nov 2026 PMID 43007495
- Arginine-engineered gold nanoclusters for doxorubicin chemiluminescence sensing. Mikrochimica acta · 29 Aug 2026 PMID 42667424
- Doxorubicin-loaded chitosan-silver nanocarrier elicits chemoresistance in liver cancer cells. Medical oncology (Northwood, London, England) · 14 Aug 2026 PMID 42599562
- Done EAZY: An Automated Procedure for 89Zr-Radiolabeling and Size-Exclusion Chromatography Purification of Nanoliposomal Anticancer Therapeutics. Molecular pharmaceutics · 29 Jun 2026 PMID 42367047
- Tailored crystallization of CaCO3 vaterite particles using ethylene glycol and carbohydrate-based biopolymers: Structure-function relationship for drug delivery. International journal of biological macromolecules · 22 Jun 2026 PMID 42331154
- Casein-coated Fe3O4 nanozymes with enhanced peroxidase-like activity for synergistic doxorubicin delivery and catalytic anticancer therapy. Journal of biotechnology · 28 May 2026 PMID 42208681
- Bioinspired polydopamine interfacial engineering of plant-derived exosomes enhances doxorubicin bioactivity in 2D and 3D breast cancer models. Biomaterials advances · 27 May 2026 PMID 42202649
Preclinical: animal, cell and lab studies (91)
- All-in-One Mitochondria-Targeted Iron-Based MOF "Nanomissiles" for Synergistically Potentiated Tumor Ferroptosis, Dual Phototherapy, and Chemotherapy. ACS nano · 10 Nov 2026 PMID 43007759
- Disulfidptosis-Driven Immune-Activated Multimodal Therapy for Glioblastoma with Systemic Safety Control. ACS nano · 10 Nov 2026 PMID 43007758
- Metformin sensitizes HepG2 liver cancer cells to doxorubicin through epithelial to mesenchymal transition and microRNA regulation. Medical oncology (Northwood, London, England) · 10 Nov 2026 PMID 43007581
- Evaluation of the antitumor effects of banana extract alone and with doxorubicin in a rat model of breast cancer. Medical oncology (Northwood, London, England) · 9 Nov 2026 PMID 43002330
- Dual-Responsive Dextran-Based Nanosystem for NIR Dual-Modal Imaging-Guided Photothermal-Chemotherapy of Breast Cancer. Biomacromolecules · 9 Nov 2026 PMID 43002041
- Self-Crosslinked Albumin Nanoparticles for Targeted Doxorubicin Delivery in Glioblastoma. Biomacromolecules · 9 Nov 2026 PMID 43002039
- Bone marrow mesenchymal stem cells-derived exosomes ameliorate doxorubicin-induced nephrotoxicity via the modulation of pyroptosis-associated signaling. Molecular medicine (Cambridge, Mass.) · 31 Oct 2026 PMID 42963580
- Effects of Alendronate and Alfacalcidol on Preventing Bone Loss in Chemotherapy-treated Soft-tissue Sarcoma. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957265
- Gold Nanourchins Potentiate Intravesical Chemotherapy by Accelerating Drug Internalization within a Short Instillation Window. ACS nano · 27 Oct 2026 PMID 42937593
- Vitamin B12-Functionalized Nanogels for pH-, and Redox-Responsive Doxorubicin Delivery. Chembiochem : a European journal of chemical biology · 26 Oct 2026 PMID 42929280
- Alpha-mangostin combined with doxorubicin-loaded hydrogel for the treatment of ovarian cancer. Journal of materials chemistry. B · 26 Oct 2026 PMID 42929270
- Dual-template molecular imprinting enables fully synthetic phosphatidylserine-targeted cancer therapy. Nanoscale · 16 Oct 2026 PMID 42885584
- Sequential Dual Nanoparticle Approach for Extracellular Matrix Remodeling and Targeted Chemotherapy through Liposome-Exosome Hybridization in Pancreatic Cancer. ACS applied materials & interfaces · 15 Oct 2026 PMID 42880885
- Folic Acid-Functionalized Liposomes Co-Loaded with Doxorubicin and Indocyanine Green for Combined Chemophotothermal Therapy of Cervical Cancer. ACS applied materials & interfaces · 13 Oct 2026 PMID 42868217
- Anisotropic microgels for spatiotemporal co-delivery of anticancer drugs. Journal of materials chemistry. B · 12 Oct 2026 PMID 42862621
- iRGD-Functionalized Graphene-Silver Nanohybrids for Enhanced Blood-Brain Barrier Transport and Tumor Penetration in Glioma Models. ACS applied bio materials · 12 Oct 2026 PMID 42861629
- Surface engineering of liposomes with quaternized hyaluronate for reduced toxicity and enhanced doxorubicin delivery. Journal of materials chemistry. B · 9 Oct 2026 PMID 42853083
- pH-Responsive Covalent Organic Framework-based Nanocarrier for Targeted Delivery of Cancer Therapeutics. ChemMedChem · 9 Oct 2026 PMID 42850959
- Tumor microenvironment-responsive injectable hydrogels for localized therapy of pancreatic cancer. Biochemical and biophysical research communications · 4 Oct 2026 PMID 42829994
- Nanocrystal maturation in doxorubicin liposomes determines functional performance: real-time insights from in situ SAXS. Journal of controlled release : official journal of the Controlled Release Society · 30 Sept 2026 PMID 42815645
- Ferritin-Based Nanomotors for Deep Glioblastoma Penetration and Enhanced Drug Delivery. Macromolecular bioscience · 30 Sept 2026 PMID 42814085
- Heart-lung-on-a-chip featuring dynamic flow-resistance capture for drug-associated cardiac dysfunction assessment under tumor-immune-conditioned drug exposure. Lab on a chip · 30 Sept 2026 PMID 42813410
- Shikonin attenuates doxorubicin-induced myocardial senescence and fibrosis in association with improved redox and mitochondrial homeostasis. Molecular biology reports · 28 Sept 2026 PMID 42803853
- Collagen targeting IL-12 combined with Doxorubicin enhances the anti-tumor effect against osteosarcoma. Journal of controlled release : official journal of the Controlled Release Society · 26 Sept 2026 PMID 42800477
- TGF-β2 promotes autophagy-mediated resistance to doxorubicin in metastatic colon cancer cells via HMGB1. Medical oncology (Northwood, London, England) · 25 Sept 2026 PMID 42789212
- Novel pyrimidine nucleoside - chitosan - silybin micelles for improving the oral absorption of doxorubicin via intestinal nucleoside transporter. Carbohydrate polymers · 24 Sept 2026 PMID 42785882
- Cholesterol-mediated endoplasmic reticulum targeting to enhance the immune-activating capability of doxorubicin for hepatocellular carcinoma. International journal of pharmaceutics · 19 Sept 2026 PMID 42763080
- Bacteria-Based Ammunition for Cascade-Amplified Chemoimmunotherapy of Ovarian Cancer. Nano letters · 9 Sept 2026 PMID 42715039
- HDAC inhibition via suberoylanilide hydroxamic acid ameliorates doxorubicin-induced cardiotoxicity. Nature communications · 4 Sept 2026 PMID 42697879
- An injectable kappa-carrageenan/konjac-glucomannan microgel platform for localized and controlled release of doxorubicin-loaded biomimetic nanoparticles. Carbohydrate polymers · 3 Sept 2026 PMID 42692648
- Zwitterionic PEGylation of Nanodrugs for Reduced Immunogenicity and Improved Drug Delivery Efficacy. ACS applied materials & interfaces · 1 Sept 2026 PMID 42680140
- Dual-targeting poly(2-oxazoline)-coated porous silicon nanoparticles for improving osteosarcoma therapy. Nanoscale · 1 Sept 2026 PMID 42677776
- Drug delivery systems modified with cell-penetrating peptide tat and folate reverse multidrug resistance in ovarian and colorectal cancer by endocytosis-mediated efficient uptake and energy production reduction. Biomedical materials (Bristol, England) · 28 Aug 2026 PMID 42665012
- Autophagy-associated exosomal microRNAs in triple-negative breast cancer: a discovery-phase study. Molecular biology reports · 22 Aug 2026 PMID 42631761
- pH-sensitive polymer-drug conjugate: An approach to evaluate the effect of the linker on doxorubicin release. Journal of pharmaceutical sciences · 21 Aug 2026 PMID 42628647
- Integrated Multi-omics Reveals CDKN1A Suppression and Metabolic Regulation as Key Mechanisms of Huangqi Guizhi Wuwu Decoction Against Doxorubicin-Induced Cardiotoxicity. Cardiovascular toxicology · 21 Aug 2026 PMID 42627580
- Dual delivery of immunostimulatory oligonucleotides and doxorubicin by magnetic nanoparticles and metal-organic frameworks for antitumor immunotherapy. Acta biomaterialia · 18 Aug 2026 PMID 42612942
- Transferrin-Conjugated Polymeric Nanoparticles via Polymerization-Induced Self-Assembly for Enhanced BBB Transport and Glioblastoma Therapy. ACS applied bio materials · 17 Aug 2026 PMID 42606070
- Dual delivery of metformin and doxorubicin via the gum acacia-gelatin nanohydrogel disrupts tunnelling nanotube-mediated breast cancer progression. Biomaterials science · 17 Aug 2026 PMID 42605874
- pH-Responsive hyaluronic acid-based nanoplatform for prolonged intraocular retention and synergistic chemotherapy of retinoblastoma. International journal of biological macromolecules · 16 Aug 2026 PMID 42604682
- Dual-cargo polymeric micelles with tumor-cell/stroma dual-targeting for synergistic eradication of drug-resistant breast cancer. Biomaterials science · 10 Aug 2026 PMID 42572978
- A bidirectional pyroptosis regulation strategy to resolve cardiotoxicity-antitumor efficacy dilemma of doxorubicin. Nanoscale · 4 Aug 2026 PMID 42548175
- Synergistic magnetic nano-chemotherapy overcomes chemoresistance in 3D breast cancer models. Mikrochimica acta · 3 Aug 2026 PMID 42545398
- Design, Synthesis, and In Vitro Evaluation of a PSMA-Targeted Doxorubicin Conjugate. ChemMedChem · 31 Jul 2026 PMID 42538127
- Doxorubicin-Induced Cytotoxicity in Adipose-Derived Stem Cells Is Associated With Altered SAPK/JNK Signaling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 31 Jul 2026 PMID 42533549
- Metal-dependent cell death in doxorubicin-induced cardiotoxicity and mitigation by luteolin: Network pharmacology and experimental verification. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 30 Jul 2026 PMID 42531631
- Differential cellular responses of breast cancer and non-tumorigenic mammary epithelial cells to a fullerene-doxorubicin complex. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 29 Jul 2026 PMID 42526255
- Targeting therapeutic nanoparticles to the glioblastoma resection margin by harnessing postoperative blood-brain barrier disruption. Science translational medicine · 29 Jul 2026 PMID 42525789
- Thermosensitive Block Copolymer Hydrogel with Embedded Catanionic Vesicles as a Localized Doxorubicin Delivery Platform for Melanoma. ACS applied bio materials · 27 Jul 2026 PMID 42504495
- Ionic Liquid-Integrated Interpenetrating Polymer Hydrogel for Injectable, Self-Healing, and Stimuli-Responsive Co-Delivery of Protein and Chemotherapeutic Agents in Breast Cancer Therapy. ACS applied bio materials · 27 Jul 2026 PMID 42504456
- Anti-PEG Single-Chain Variable-Fragment Antibody-Assisted In Vivo Process Decoding of PEGylated Nanomedicines. ACS nano · 27 Jul 2026 PMID 42503863
- Cellular effects of combined Ctn-2 peptide and doxorubicin treatment in breast cancer cells: A preliminary study of membrane interaction, ROS production, and cell cycle distribution. Molecular biology reports · 25 Jul 2026 PMID 42501149
- Tailoring pH-responsive charge-conversional interfaces in ionizable lipid-based nanoliposomes for synchronized co-delivery and synergistic therapy of triple-negative breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 23 Jul 2026 PMID 42492401
- A clinical data- and AI-supported engineered fusion vesicle system for enhanced tumor-targeted drug delivery and immunochemotherapeutic synergy. Journal of controlled release : official journal of the Controlled Release Society · 22 Jul 2026 PMID 42486279
- A scheme to tackle the dilemma from hepatoma cells under doxorubicin-resistant surroundings: a brightness or a silhouette. Artificial cells, nanomedicine, and biotechnology · 22 Jul 2026 PMID 42482449
- Biodegradable dual-responsive amino acid-based zwitterionic nanogels for enhanced cancer therapy. Journal of materials chemistry. B · 20 Jul 2026 PMID 42475274
- Hybrid Response Surface-Machine Learning Optimization of Doxorubicin-Loaded Chitosan Nanoparticles. ACS applied bio materials · 15 Jul 2026 PMID 42454628
- Dual-responsive self-assembled nanomicelle based on low molecular weight chitosan enhanced the antitumor effect of doxorubicin by disrupting intracellular redox homeostasis. Carbohydrate research · 14 Jul 2026 PMID 42447726
- Mechanistic evaluation of liposome-amyloid composite nanocarriers for doxorubicin delivery: Linking release kinetics with pharmacokinetic behavior. Biochimica et biophysica acta. Biomembranes · 11 Jul 2026 PMID 42435790
- Rutin-enabled improved systemic exposure of doxorubicin via nanostructured lipid carriers: a proof of concept through novel LC-MS/MS analysis. Drug development and industrial pharmacy · 11 Jul 2026 PMID 42435317
- pH-responsive microneedle patches based on poly(dextran-co-methacrylic acid) hydrogels for controlled drug release. International journal of biological macromolecules · 9 Jul 2026 PMID 42425357
- Dual-trigger hyaluronic acid nanoprodrug incorporating a 2-nitrobenzenesulfonyl linker for CD44-targeted and glutathione-responsive drug delivery. International journal of pharmaceutics · 4 Jul 2026 PMID 42401301
- Multicomponent Micelles with Boosted Stability of Iminoboronates. Biomacromolecules · 3 Jul 2026 PMID 42397949
- Graphene oxide functionalized with polyamidoamine dendrimer as a drug delivery system for human breast cells. Biomaterials advances · 2 Jul 2026 PMID 42391792
- Pulsed Electromagnetic Field Increases Doxorubicin-induced Mitotic Slippage in MDA-MB-231 Breast Cancer Cells. Anticancer research · 29 Jun 2026 PMID 42373288
- Anticancer Effects of Nortriptyline Hydrochloride in Osteosarcoma Cells Including Doxorubicin-resistant Cells. Anticancer research · 29 Jun 2026 PMID 42373283
- Surface engineering of graphene as a novel nano-carrier for doxorubicin using sugar-based deep eutectic systems. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 29 Jun 2026 PMID 42372833
- Downregulation of SLC44A4 in nasopharyngeal carcinoma is associated with malignant progression, B-cell/TLS-related immune features, and sensitivity to DNA-damaging agents. PloS one · 26 Jun 2026 PMID 42361082
- Synergistic anticancer activity of antimicrobial peptide nisin and doxorubicin against breast cancer cells via modulation of membrane permeability. PloS one · 23 Jun 2026 PMID 42335141
- Tumour endothelial cell reprogramming orchestrates angiocrine signalling to drive chemoresistance in breast cancer. Angiogenesis · 22 Jun 2026 PMID 42329467
- Laser-programmable glycosaminoglycan-based nanocarriers co-deliver hypocrellin B and doxorubicin for spatiotemporal chemo-photothermal therapy of hepatocellular carcinoma. Colloids and surfaces. B, Biointerfaces · 20 Jun 2026 PMID 42322922
- An intelligent responsive nanoplatform based on a DNA nanoflowers/Mn:CuS hybrid for targeted and synergistic cancer therapy. Journal of materials chemistry. B · 16 Jun 2026 PMID 42300245
- Lactate-sensitive nanomachines for enzyme-controlled drug delivery in cancer therapy. Journal of materials chemistry. B · 16 Jun 2026 PMID 42300004
- Co-Delivery of Chemo and Immune Drugs by Prussian Blue Nanocubes for Combinational Therapy and T1-T2W MR Imaging of MDA-MB-231. ACS applied bio materials · 16 Jun 2026 PMID 42299821
- Programmable nanocarriers with reversible ligand shielding and acid-triggered burst release for sequential tumor penetration and intracellular drug delivery. Colloids and surfaces. B, Biointerfaces · 15 Jun 2026 PMID 42296941
- Exosomes as Biomimetic Nanoplatforms for Synergistic Targeted Chemotherapy and Photothermal Treatment of Breast Cancer. Journal of biochemical and molecular toxicology · 15 Jun 2026 PMID 42290533
- Colloidal virus-like nanoparticles for targeted delivery of doxorubicin to non-small cell lung cancer using a cell-internalizing peptide. Colloids and surfaces. B, Biointerfaces · 13 Jun 2026 PMID 42287827
- Multifunctional DNA Nanoplatform Based on CuInS/ZnS QDs and Rolling Circle Amplification for Synergistic PTT/CDT/CT of Multidrug Resistant Cancer Cells. ACS applied materials & interfaces · 12 Jun 2026 PMID 42281380
- GSH-activatable rare-earth nanoprobe for NIR-II fluorescence imaging-guided surgery and enhanced chemotherapy/chemodynamic therapy of breast cancer. Cancer letters · 11 Jun 2026 PMID 42276408
- Functionalization of cyclotriveratrilene with tetrazole and phenothiazine for doxorubicin coordination and delivery. Bioorganic & medicinal chemistry · 10 Jun 2026 PMID 42269374
- Dual-functional MXene-integrated GelMA microspheres for synergistic chemo/photothermal therapy: In vitro 2D/3D multi-cancer evaluation and in vivo breast cancer validation. International journal of biological macromolecules · 7 Jun 2026 PMID 42251874
- A charge-reversible hyaluronic acid prodrug nanoplatform for synergistically enhanced tumor-targeted doxorubicin delivery. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 6 Jun 2026 PMID 42250822
- Synergistic drug repurposing strategy identifies doxorubicin and paclitaxel as potential combination therapy for diffuse large B-cell lymphoma. Computers in biology and medicine · 3 Jun 2026 PMID 42235267
- Biomimetic Nanoparticles Based on Tumor Cell Membrane Co-loaded with Vitamin E and Doxorubicin for Targeted Synergistic Treatment of Bladder Cancer. ACS applied bio materials · 1 Jun 2026 PMID 42223068
- Assessment of Doxorubicin Internalization and Cytotoxicity in Primary Tumor Spheroids After Collagen Digestion. Current protocols · 1 Jun 2026 PMID 42222873
- Focused acoustic vortex-mediated targeted aggregation of engineered bacteria for in situ antibody production to enhance immunotherapy. Acta biomaterialia · 30 May 2026 PMID 42217659
- Molecular Boomerangs Against Cancer: Design, Synthesis, Biological Evaluation, and In Silico Study of Novel Dual PARP-1/EGFR Inhibitors. Drug development research · 28 May 2026 PMID 42207930
- Nitric oxide dual-enhanced nanosystem boosts ferroptosis-chemotherapy synergy for tumor therapy. Scientific reports · 26 May 2026 PMID 42192119
- Development of a Light-Triggered Biotin-Bioorthogonal System for Targeted Anti-Tumor Therapy. Journal of medicinal chemistry · 26 May 2026 PMID 42187134
- A microphysiological spheroid system for modeling glioblastoma structure and therapy response. Biochemical and biophysical research communications · 22 May 2026 PMID 42172901
- Self-Assembly, Phase Behavior, and Structure of Phenylalanine Alkyl Esters: Characterization of Lauryl Phenylalaninate-Lauryl Sulfate Catanionic Liposomes and Doxorubicin Encapsulation and Release. Langmuir : the ACS journal of surfaces and colloids · 20 May 2026 PMID 42159400
Unclassified: not yet indexed with MeSH (3)
- Correlating the C-5 Induction Effect on Uracil-Based Nucleoside Lipid Nanoparticles for Enhanced Redox-Mediated Therapeutic Efficacy in Hepatocellular Carcinoma. ACS applied bio materials · 5 Oct 2026 PMID 42834024
- Multi-Omics Analysis Identifies Paxillin as a Biomarker of Doxorubicin Resistance via Cytoskeletal Remodeling and Immune Exhaustion. Journal of proteome research · 18 Jun 2026 PMID 42313513
- Effective ropivacaine delivery using lipid nanoparticles enables simultaneous cancer therapy and pain control. International journal of pharmaceutics · 31 May 2026 PMID 42219130
Written from 104 PubMed abstracts, each one listed by PMID above. Published: 2026-07-02. Last written: 2026-09-11 by GPT. Corrections: 2026-09-26 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.